HR Execs on the Move

JenaValve

www.jenavalve.com

 
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million
  • www.jenavalve.com
  • 1000 N. West Street Suite 1200
    Wilmington, DE USA 19801
  • Phone: 302.295.4897

Executives

Name Title Contact Details
Kevin Chu
Director of R&D, Catheter Development Profile

Similar Companies

SportsArt

SportsArt is the fitness industry leader in eco-innovation, unique design and green manufacturing excellence; and the only fitness company able to harness human energy and convert it into utility-grade electricity. We`ve built our reputation through rebuilding and sustaining lives in the fitness, medical rehabilitation, performance and wellness markets.

Medical Express

Medical Express is a Grants Pass, OR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Eastern States Eyewear

Eastern States Eyewear is a Elmont, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Drug Aid Pharmacy

Drug Aid Pharmacy is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

InfraScan

InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.